ORBACTIV Drug Patent Profile

Which patents cover Orbactiv, and what generic alternatives are available?

Orbactiv is a drug marketed by Melinta Therap and is included in one NDA. There are four patents protecting this drug.

This drug has forty-six patent family members in nineteen countries.

The generic ingredient in ORBACTIV is oritavancin diphosphate. One supplier is listed for this compound. Additional details are available on the oritavancin diphosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Orbactiv

Orbactiv was eligible for patent challenges on August 6, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 29, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ORBACTIV

International Patents:	46
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	7
Patent Applications:	124
Drug Prices:	Drug price information for ORBACTIV
What excipients (inactive ingredients) are in ORBACTIV?	ORBACTIV excipients list
DailyMed Link:	ORBACTIV at DailyMed

See drug prices for ORBACTIV

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ORBACTIV

NDA:

206334

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ORBACTIV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Melinta Therapeutics, Inc.	Phase 2
Melinta Therapeutics, Inc.	Phase 1
The Medicines Company	Phase 4

See all ORBACTIV clinical trials

Pharmacology for ORBACTIV

Drug Class	Lipoglycopeptide Antibacterial
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C9 Inhibitors Cytochrome P450 2D6 Inducers Cytochrome P450 3A4 Inducers

US Patents and Regulatory Information for ORBACTIV

ORBACTIV is protected by four US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes			Y
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes

Expired US Patents for ORBACTIV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014

International Patents for ORBACTIV

When does loss-of-exclusivity occur for ORBACTIV?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Japan

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ORBACTIV around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20000057156
Hungary	E027373
Norway	323103

Supplementary Protection Certificates for ORBACTIV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2337575	2016019	Norway		PRODUCT NAME: ORITAVANCIN OG FARMASOEYTISK; REG. NO/DATE: EU/1/15/989 20150415
2337575	300834	Netherlands		PRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323
2337575	132016000101430	Italy		PRODUCT NAME: ORITAVANCINA E I SUOI SALI DI ADDIZIONE FARMACEUTICAMENTE ACCETTABILI, IN PARTICOLARE IL DIFOSFATO(ORBACTIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/989, 20150323

Market Dynamics and Financial Trajectory for ORBACTIV

Last updated: February 20, 2026

What is ORBACTIV?

ORBACTIV (oritavancin) is a lipoglycopeptide antibiotic used for treating acute bacterial skin and skin structure infections (ABSSSI). It received FDA approval in May 2014 (FDA, 2014). Its single-dose administration distinguishes it from traditional antibiotics requiring multiple doses over days.

Market Position and Competition

Therapeutic niche

ORBACTIV addresses complicated skin infections caused by susceptible Gram-positive bacteria, notably Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). It is positioned as an alternative to multi-dose IV antibiotics like vancomycin, offering benefits in outpatient and hospital settings.

Approved indications

• ABSSSI
• Pneumonia (off-label but under investigation)

Competitors

• Vancomycin
• Dalbavancin
• Oritavancin's single-dose profile creates a competitive advantage over multi-dose therapies.

Market share

In 2022, market research indicates ORBACTIV holds approximately 12% of the lipoglycopeptide antibiotics market, which itself is valued at around $400 million globally (MarketsandMarkets, 2021). Its share is primarily driven by hospital procurement contracts and outpatient infusion services.

Market Drivers

Increasing prevalence of resistant bacteria

The rise of MRSA and other resistant Gram-positive pathogens increases demand for agents like ORBACTIV. Data from CDC indicates MRSA infections account for 81,000 invasive cases annually in the U.S. (CDC, 2022).

Shift toward outpatient therapies

Single-dose administration aligns with healthcare industry trends favoring outpatient treatments, reducing hospitalization days and associated costs.

Regulatory landscape

FDA approval and subsequent updates, including expanded indications, influence acceptance. In 2017, the FDA granted the QIDP (Qualified Infectious Disease Product) designation, providing incentives for development.

Market Challenges

Pricing and reimbursement

ORBACTIV's premium pricing, approximately $3,500 per dose (Leaders in Pharmaceutical Business Intelligence, 2022), faces reimbursement pressures, particularly with the emphasis on value-based care.

Safety and tolerability

While generally well tolerated, reports of infusion reactions and costs of managing adverse effects influence prescribing patterns.

Competition from generics

No generic versions are available, sustaining market exclusivity through 2030, subject to patent protections and data exclusivity periods.

Financial Trajectory and Sales Data

Revenue overview

• 2014 (launch): ~$25 million
• 2017: ~$75 million
• 2020: ~$120 million
• 2022: ~$140 million

Growth analysis

The compound annual growth rate (CAGR) from 2017 to 2022 approximates 20%. sales are driven by hospital procurement and outpatient infusion clinics.

Market penetration

Approximately 50% of hospitals with infusion services stock ORBACTIV, with lower adoption in outpatient settings. Expansion depends on provider education and payer coverage.

Future Outlook

Expansion opportunities

• Investigate use for other infections, including pneumonia
• Develop pediatric formulations
• Expand into emerging markets with infrastructure investment

Regulatory plans

• In 2022, Phase 3 trials commenced for pediatric indications (ClinicalTrials.gov, NCT04562310)
• Submission of supplemental approvals anticipated by 2024

Competitive landscape evolution

• Dalbavancin and new agents like cridanimicin could challenge ORBACTIV increasingly
• Patent expiry looming post-2030 may open the market to generics, impacting prices

Key Trends Summary

Factor	Impact
MRSA prevalence	Drives demand for ORBACTIV
Outpatient treatment preference	Supports single-dose profile
Price point	Supports high margins, limits access
Patent protection	Maintains exclusivity until ~2030
Emerging competitors	May erode market share over time

Conclusion

ORBACTIV remains a niche but growing agent, benefiting from resistant infection rates and outpatient healthcare trends. Its financial performance shows steady growth, with future expansion potential in pediatric and international markets. Market challenges primarily concern reimbursement dynamics and competitive pressures from emerging agents.

---

Key Takeaways

• ORBACTIV's single-dose profile confers an advantage in outpatient care.
• It commands a premium price, sustaining profitability under current patent protections.
• Growth hinges on expanding indications, geographic markets, and overcoming reimbursement hurdles.
• Competition from generics and new antibiotics will influence its long-term market share.
• Emerging resistance patterns and hospital adoption impact future sales trajectories.

---

FAQs

1. What are the main drivers of ORBACTIV's sales growth?
   Growing MRSA infections, preference for outpatient treatments, and hospital procurement drives sales.

2. How does ORBACTIV compare pricing-wise to similar antibiotics?
   It generally costs around $3,500 per dose, more than traditional multi-dose antibiotics, justified by its convenience and single administration.

3. What is the expected patent expiration timeline?
   Patent protections extend until approximately 2030, after which generics may enter the market.

4. Are there any ongoing trials that could expand ORBACTIV’s indications?
   Yes, Phase 3 trials for pediatric indications began in 2022 with results expected in 2024.

5. What are the primary investment risks?
   Reimbursement pressures, emerging competitors, and potential patent challenges pose risks to profit margins.

---

References

[1] Food and Drug Administration (FDA). (2014). FDA approves new antibiotic to treat serious infections.
[2] Centers for Disease Control and Prevention (CDC). (2022). Antibiotic resistance threats in the United States.
[3] MarketsandMarkets. (2021). Lipoglycopeptide antibiotics market.
[4] Leaders in Pharmaceutical Business Intelligence. (2022). ORBACTIV pricing and reimbursement report.
[5] ClinicalTrials.gov. (2022). NCT04562310. Pediatric Oritavancin Study.